{"url_path":"/sec/vnrx/8-k/2026-06-10/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-10","source_url":"https://www.sec.gov/Archives/edgar/data/93314/0001477932-26-003740-index.html","accession_number":"0001477932-26-003740","cik":"0000093314","ticker":"VNRX","issuer_name":"VOLITIONRX LTD","edgar_url":"https://www.sec.gov/Archives/edgar/data/93314/0001477932-26-003740-index.html","primary_entity_key":"0000093314","primary_entity_name":"VOLITIONRX LTD"},"word_count":242,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit**\n\n**Number**\n\n \n\n**Description**\n\n[1.1*](vnrx_ex11.htm)\n\n \n\n[Placement Agency Agreement, dated June 7, 2026, by and between VolitionRx Limited and Maxim Group LLC](vnrx_ex11.htm)\n\n[4.1*](vnrx_ex41.htm)\n\n \n\n[Form of Warrant](vnrx_ex41.htm)\n\n[4.2*](vnrx_ex42.htm)\n\n \n\n[Warrant Agent Agreement, dated June 9, 2026, by and between VolitionRx Limited and VStock Transfer, LLC](vnrx_ex42.htm)\n\n[5.1](vnrx_ex51.htm)\n\n \n\n[Opinion of Stradling, Yocca, Carlson & Rauth LLP](vnrx_ex51.htm)\n\n[10.1*](vnrx_ex101.htm)\n\n \n\n[Form of Securities Purchase Agreement, dated as of June 7, 2026, by and among the Company and the purchasers on the signature pages thereto](vnrx_ex101.htm)\n\n[23.1](vnrx_ex51.htm)\n\n \n\n[Consent of Stradling, Yocca, Carlson & Rauth LLP (contained in Exhibit 5.1)](vnrx_ex51.htm)\n\n[99.1](vnrx_ex991.htm)\n\n \n\n[Press Release, dated June 7, 2026](vnrx_ex991.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n* Certain of the schedules (and similar attachments) to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K under the Securities Act of 1933, as amended, because they do not contain information material to an investment or voting decision and that information is not otherwise disclosed in the exhibit or disclosure document. The Company agrees to furnish a copy of all omitted schedules (or similar attachments) to the SEC upon its request.\n\n \n\n \n\n3\n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n**VOLITIONRX LIMITED**\n\n \n\n \n\n \n\n \n\nDate: June 9, 2026\n\nBy:\n\n*/s/ Cameron Reynolds*\n\n \n\n \n\n \n\nCameron Reynolds\n\n \n\n \n\n \n\nChief Executive Officer & President\n\n \n\n \n\n \n\n4"}